| Jun 26 |
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
| Jun 19 |
3 Penny Stocks Poised for Major Upside Over the Next 5 Years
|
| Jun 11 |
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
|
| Jun 7 |
Savara: The Binary Bet On Phase 3 Data
|
| May 29 |
Savara to Present at the Jefferies Global Healthcare Conference
|
| May 19 |
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
|
